Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1988 5
1989 2
1990 3
1991 2
1992 2
1993 1
1994 1
1995 1
1996 3
1997 2
1999 1
2000 3
2001 3
2002 1
2003 2
2005 1
2006 4
2007 7
2008 5
2009 8
2010 5
2011 6
2012 10
2013 6
2014 13
2015 11
2016 15
2017 14
2018 9
2019 9
2020 16
2021 9
2022 17
2023 20
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Results by year

Filters applied: . Clear all
Page 1
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.
Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, Ciceri F, Cornelissen J, Malladi R, Duarte RF, Giebel S, Greinix H, Holler E, Lawitschka A, Mielke S, Mohty M, Arat M, Nagler A, Passweg J, Schoemans H, Socié G, Solano C, Vrhovac R, Zeiser R, Kröger N, Basak GW. Penack O, et al. Lancet Haematol. 2020 Feb;7(2):e157-e167. doi: 10.1016/S2352-3026(19)30256-X. Lancet Haematol. 2020. PMID: 32004485 Review.
Key updates to these recommendations include a broader use of rabbit anti-T-cell globulin; lower steroid doses for the management of grade 2 acute GVHD with isolated skin or upper gastrointestinal tract manifestations; fluticasone, azithromycin, and montelukast should be u …
Key updates to these recommendations include a broader use of rabbit anti-T-cell globulin; lower steroid doses for the management of grade 2 …
Update in the Management of Basal Cell Carcinoma.
Basset-Seguin N, Herms F. Basset-Seguin N, et al. Acta Derm Venereol. 2020 Jun 3;100(11):adv00140. doi: 10.2340/00015555-3495. Acta Derm Venereol. 2020. PMID: 32346750 Free PMC article. Review.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. ...Characteristic molecular events in these tumours are: (i) activation of the hedgehog pathway, which has allowed the development of hedgehog inhibitors for …
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. ...Characteristic …
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.
Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A, Ederhy S, Feuillet S, François H, Lazarovici J, Le Pavec J, De Martin E, Mateus C, Michot JM, Samuel D, Soria JC, Robert C, Eggermont A, Marabelle A. Champiat S, et al. Ann Oncol. 2016 Apr;27(4):559-74. doi: 10.1093/annonc/mdv623. Epub 2015 Dec 28. Ann Oncol. 2016. PMID: 26715621 Free article. Review.
Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1 have recently obtained approval for the treatment of metastatic melanoma and advanced/refractory non small-cell lung cancers. Therefore, their use will not be limited anymore to selected …
Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1 have recently obtained approval for the treatment of …
Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?
Kazemi MH, Sadri M, Najafi A, Rahimi A, Baghernejadan Z, Khorramdelazad H, Falak R. Kazemi MH, et al. Front Immunol. 2022 Oct 28;13:1018962. doi: 10.3389/fimmu.2022.1018962. eCollection 2022. Front Immunol. 2022. PMID: 36389779 Free PMC article. Review.
Recent advances in understanding TME, immune exhaustion, and immune checkpoints have paved the way for TIL therapy regimens. Nowadays, TIL therapy has regained attention as a safe personalized immunotherapy, and currently, several clinical trials are evaluating the …
Recent advances in understanding TME, immune exhaustion, and immune checkpoints have paved the way for TIL therapy regimens. Nowadays …
Single-cell characterization of anti-LAG-3 and anti-PD-1 combination treatment in patients with melanoma.
Huuhtanen J, Kasanen H, Peltola K, Lönnberg T, Glumoff V, Brück O, Dufva O, Peltonen K, Vikkula J, Jokinen E, Ilander M, Lee MH, Mäkelä S, Nyakas M, Li B, Hernberg M, Bono P, Lähdesmäki H, Kreutzman A, Mustjoki S. Huuhtanen J, et al. J Clin Invest. 2023 Mar 15;133(6):e164809. doi: 10.1172/JCI164809. J Clin Invest. 2023. PMID: 36719749 Free PMC article.
BackgroundRelatlimab plus nivolumab (anti-lymphocyte-activation gene 3 plus anti-programmed death 1 [anti-LAG-3+anti-PD-1]) has been approved by the FDA as a first-line therapy for stage III/IV melanoma, but its detailed effect on the immune system is unknown.MethodsWe eva …
BackgroundRelatlimab plus nivolumab (anti-lymphocyte-activation gene 3 plus anti-programmed death 1 [anti-LAG-3+anti-PD-1]) has been approve …
The Evolving Treatment Landscape of Merkel Cell Carcinoma.
Singh N, McClure EM, Akaike T, Park SY, Huynh ET, Goff PH, Nghiem P. Singh N, et al. Curr Treat Options Oncol. 2023 Sep;24(9):1231-1258. doi: 10.1007/s11864-023-01118-8. Epub 2023 Jul 5. Curr Treat Options Oncol. 2023. PMID: 37403007 Review.
Multidisciplinary and personalized care is therefore paramount, based on patient preferences regarding risks and benefits. ...Cytotoxic chemotherapy is sometimes used for debulking disease or in patients who cannot tolerate ICI. ICI-refractory disease is the major p …
Multidisciplinary and personalized care is therefore paramount, based on patient preferences regarding risks and benefits. ...Cytotox …
Diagnosis, treatment, and genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A review.
Wang Y, Xiao L, Yin L, Zhou L, Deng Y, Deng H. Wang Y, et al. Medicine (Baltimore). 2023 Feb 17;102(7):e32904. doi: 10.1097/MD.0000000000032904. Medicine (Baltimore). 2023. PMID: 36800625 Free PMC article. Review.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly aggressive and extremely rare hematologic disease with a poor prognosis, involving mainly the skin and bone marrow. ...The emergence of targeted drugs has filled the gap left by traditional therapie …
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly aggressive and extremely rare hematologic disease with a poor progno …
Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer.
Jhawar SR, Wang SJ, Thandoni A, Bommareddy PK, Newman JH, Marzo AL, Kuzel TM, Gupta V, Reiser J, Daniels P, Schiff D, Mitchell D, LeBoeuf NR, Simmons C, Goyal S, Lasfar A, Guevara-Patino JA, Haffty BG, Kaufman HL, Silk AW, Zloza A, Giurini EF. Jhawar SR, et al. J Immunother Cancer. 2023 Jul;11(7):e006780. doi: 10.1136/jitc-2023-006780. J Immunother Cancer. 2023. PMID: 37433716 Free PMC article.
METHODS: To investigate the activity of this combination therapy, we used in vitro mouse and human cancer cell lines as well as a mouse model of skin cancer. ...We report tumor reduction and prolonged survival of a patient with skin cancer treated with combin …
METHODS: To investigate the activity of this combination therapy, we used in vitro mouse and human cancer cell lines as well as a mou …
New and emerging drugs for the treatment of advanced cutaneous squamous cell carcinoma.
Bonini F, de Sousa LG, Ferrarotto R. Bonini F, et al. Expert Opin Emerg Drugs. 2023 Dec;28(2):97-106. doi: 10.1080/14728214.2023.2208345. Epub 2023 Jun 23. Expert Opin Emerg Drugs. 2023. PMID: 37144289 Review.
A subset of patients are not candidates for curative-intent therapies due to extent of loco-regional disease, refractoriness to prior local therapy, or presence of distant metastasis. ...Until 2018, systemic therapy options to treat patients with advan …
A subset of patients are not candidates for curative-intent therapies due to extent of loco-regional disease, refractoriness t …
Expert Consensus on the Management of Adverse Events During Treatment with Lenvatinib for Thyroid Cancer.
Reed N, Glen H, Gerrard G, Good J, Lei M, Lyon AR, Strachan M, Wadsley J, Newbold K. Reed N, et al. Clin Oncol (R Coll Radiol). 2020 May;32(5):e145-e153. doi: 10.1016/j.clon.2019.11.010. Epub 2019 Dec 13. Clin Oncol (R Coll Radiol). 2020. PMID: 31843241 Review.
PubMed was searched on 24 October 2017; the search terms were 'lenvatinib' and 'thyroid cancer'. RESULTS: Hypertension, diarrhoea, weight loss, skin toxicities and cardiovascular adverse events were considered. ...For grade >3 proteinuria, lenvatinib should be interrupt …
PubMed was searched on 24 October 2017; the search terms were 'lenvatinib' and 'thyroid cancer'. RESULTS: Hypertension, diarrhoea, weight lo …
195 results